HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell

Advance your COVID-19 studies with SBI

Explore interactions of the SARS-CoV-2 nucleocapsid protein with host proteins and more using the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. Built using our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, this stable cell line overexpresses the SARS-CoV-2 "N" protein—the nucleocapsid—from the CMV promoter, with a separate EF1α promoter driving expression of the puromycin resistance gene for selection.
Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
The overexpression lentivector is also available as plasmid and pre-packaged virus

See all of our COVID-19-related Expression Constructs

Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. We transduced the SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, we extracted total protein and analyzed nucleocapsid protein expression via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.